undamentalytics Newsletter
Sign in

Teladoc Health, Inc. key statistics and ratios

In fiscal 2025, Teladoc Health, Inc. had return on equity of -13.9% and a net margin of -7.9%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Net margin−30.2%−39.1%−75.0%−60.3%−45.8%−23.2%−17.9%−44.3%−21.1%−567.5%−8.5%−39.0%−7.9%−6.3%
Return on equity——−104.5%−36.3%−27.0%−12.4%−9.8%−5.7%−2.7%−148.8%−9.5%−52.5%−13.9%−11.6%
Return on assets—−18.6%−36.1%−27.8%−18.9%−8.3%−6.3%−5.0%−2.4%−123.7%−5.0%−25.3%−6.3%−5.5%
R&D as % of revenue17.7%17.4%18.4%17.7%14.8%13.0%11.7%15.1%15.3%13.9%13.4%12.0%11.0%10.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · September 30, 2026
What it owns · $2.8bn
Short-term assets $1.2bnLonger-term assets $1.5bn
What it owes, and who funded it · $2.8bn
Short-term liabilities $1.4bnLonger-term liabilities $65mShareholders' equity $1.3bn
  • Short-term assets cover short-term liabilities $1.2bn of assets due within a year against $1.4bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.2bn short-term assets against $65m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$163m against $20m of interest.

From Teladoc Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

36 /100

Weak moat

How hard Teladoc Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -7.7% of total assets over 10 years.

  • Pricing power 19 / 20

    Gross margin has been a median 70.2%, moving by 3.4 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -27.0%; its worst year was -425.2%.

  • Cash conversion 11 / 20

    Free cash flow was positive in 7 of 10 years, at a median 8.6% of revenue.

  • Discipline 2 / 20

    The diluted share count rose 135.3% over five years; stock-based pay has been a median 8.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (41 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: TDOC vs VEEVTDOC vs TEMTDOC vs WAY

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Teladoc Health, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Teladoc Health, Inc.